Campbell & CO Investment Adviser LLC Acquires New Stake in Agilent Technologies, Inc. $A

Key Points

• Campbell & CO Investment Adviser LLC has purchased a new stake in Agilent Technologies, Inc., acquiring 22,115 shares valued at approximately $2.6 million during the 1st quarter.
• Wall Street analysts have adjusted their price targets for Agilent Technologies, with ratings ranging from "buy" to "neutral," and a consensus price target of $139.77.
• CEO Padraig Mcdonnell sold 1,508 shares at an average price of $117.44, reducing his holding in the company by 3.87%.

Campbell & CO Investment Adviser LLC purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 22,115 shares of the medical research company's stock, valued at approximately $2,587,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agilent Technologies by 13.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after purchasing an additional 4,362 shares during the period. Assenagon Asset Management S.A. boosted its stake in Agilent Technologies by 8.3% in the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after purchasing an additional 2,371 shares during the period. Alps Advisors Inc. boosted its stake in Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after purchasing an additional 3,040 shares during the period. D.A. Davidson & CO. boosted its position in shares of Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock valued at $1,108,000 after acquiring an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. boosted its position in shares of Agilent Technologies by 7.6% during the 1st quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock valued at $89,870,000 after acquiring an additional 54,302 shares during the last quarter.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Agilent Technologies Stock Up 5.5%

Agilent Technologies stock traded up $6.48 during mid-day trading on Thursday, hitting $125.17. The company had a trading volume of 3,886,267 shares, compared to its average volume of 1,953,399. The company has a current ratio of 2.09, a quick ratio of 1.60 and a debt-to-equity ratio of 0.55. The stock's 50 day moving average price is $117.99 and its two-hundred day moving average price is $116.89. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a market capitalization of $35.56 billion, a PE ratio of 30.91, a price-to-earnings-growth ratio of 3.59 and a beta of 1.22.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the company posted $1.32 earnings per share. The company's revenue for the quarter was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on A shares. Robert W. Baird lifted their price target on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday. Wells Fargo & Company lifted their price target on Agilent Technologies from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday. Barclays lifted their price target on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Tuesday, June 24th. Evercore ISI cut their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research report on Thursday. Finally, TD Cowen lifted their price objective on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Agilent Technologies currently has a consensus rating of "Moderate Buy" and an average price target of $139.25.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.